On Jul. 6, 2020, Emergent BioSolutions announced a five-year manufacturing services agreement with Janssen Pharmaceuticals, a Johnson & Johnson subsidiary, for large-scale drug substance manufacturing for Johnson & Johnsonﾒs investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVacﾮ technology. Emergent will provide contract development and manufacturing (CDMO) services to produce drug substance at large scale over five years, valued at approximately $480 million for the first two years.